SIETES :: 92082 citas

Resultados de la búsqueda por HEMATOLOGÍA REFINAR BÚSQUEDA

1.

Anónimo. FDA approves second CAR T-cell therapy, this time for non-Hodgkin lymphoma. DIA Daily 2017:1. [Ref.ID 102098]

2.

Anónimo. Clozapina: modificación del programa de seguimiento de los pacientes. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:4 de octubre. [Ref.ID 102091]

3.

Chang S-H, Chou I-J, Yeh Y-H, Chiou M-J, Wen M-S, Kuo C-T, See L-C, Kuo C-F. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 2017;318:1250-9. [Ref.ID 102073]

4.

Naci H, Smalley KR, Kesselheim AS. Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration. JAMA 2017;318:626-36. [Ref.ID 102056]

5.

Sugiyama T. Osteoporotic fractures associated with dabigatran vs warfarin. JAMA 2017;318:90-1. [Ref.ID 102054]

6.

Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med 2017;177:1308-15. [Ref.ID 102042]

7.

Anónimo. Lénalidomide et lymphome du manteau en rechute ou réfractaire. Prescrire 2017;37:572-4. [Ref.ID 102041]

8.

Anónimo. FDA Approves CAR-T therapy for treatment of childhood leukemia. DIA Daily 2017:1. [Ref.ID 102036]

9.

Anónimo. Gilead agrees to acquire Kite Pharma in $11.9 billion deal. DIA Daily 2017:1. [Ref.ID 102034]

10.

Gicquel C, Moulis F, Chenaf C, Gouraud A, Drici M, Bondon-Guitton E, Montastruc F, Montastruc J-L. Duloxetine and gingival bleeding: a case-report and reviews of the French and world Pharmacovigilance databases and literature. Eur J Clin Pharmacol 2017;73:1197-8. [Ref.ID 102026]

11.

Gieling EM, van den Ham HA, van Onzenoort H, Bos J, Kramers C, de Boer A, de Vries F, Burden AM. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. Br J Clin Pharmacol 2017;83:1844-59. [Ref.ID 102014]

12.

Anónimo. Daratumumab en monothérapie et myélome multiple en rechute et réfractaire. Prescrire 2017;37:491-3. [Ref.ID 102005]

13.

Lehto M, Niiranen J, Korhonen P, Mehtälä J, Khanfir H, Hoti F, Lassila R, Raatikainen P. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry. Pharmacoepidemiol Drug Saf 2017;26:657-65. [Ref.ID 101963]

14.

Komen J, Forslund T, Hjemdahl P, Andersen M, Wettermark B. Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. Br J Clin Pharmacol 2017;83:642-52. [Ref.ID 101934]

15.

Walter SR, Day RO, Gallego B, Westbrook JI. The impact of serious adverse drug reactions: a population-based study of a decade of hospital admissions in New South Wales, Australia. Br J Clin Pharmacol 2017;83:416-26. [Ref.ID 101933]

16.

Ramírez E, Medrano-Casique N, Tong HY, Bellón T, Cabañas R, Fiandor A, González-Ramos J, Herranz P, Trigo E, Muñoz M, Borobia AM, Carcas AJ, Frías J. Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital. Br J Clin Pharmacol 2017;83:400-15. [Ref.ID 101932]

17.

Thomas K. Celgene to pay $280 Million to settle fraud suit over cancer drugs. N Y Times (Print) 2017:1. [Ref.ID 101924]

18.

Giner-Soriano M, Roso-Llorach A, Vedia Urgell C, Castells X, Capellà D, Ferreira-González I, Elorza-Ricart J-M, Casajuana M, Troncoso Mariño A, Diogene E, Bolíbar B, Violan C, Morros R. Effectiveness and safety of drugs used for stroke prevention in a cohort of non-valvular atrial fibrillation patients from a primary care electronic database. Pharmacoepidemiol Drug Saf 2017;26:enero. [Ref.ID 101916]

19.

Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young J, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017:1. [Ref.ID 101908]

20.

Anónimo. Ibrutinib et leucémie lymphoïde chronique en première ligne. Prescrire 2017;37:335-6. [Ref.ID 101645]